
--- Page 1 ---
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
DECISION MEMORANDUM
ASSAY ONLY TEMPLATE
A. 510(k) Number:
k161687
B. Purpose for Submission:
Addition of a diagnostic claim to an existing device.
C. Measurand:
Whole Blood Glycated Hemoglobin (HbA1c)
D. Type of Test:
Ion-Exchange Quantitative High Performance Liquid Chromatography
E. Applicant:
Bio-Rad Laboratories, Inc.
F. Proprietary and Established Names:
D-10 Hemoglobin A1c Program
G. Regulatory Information:
Product
Regulation Name Classification Regulation Section Panel
Code
Hemoglobin A1c Test Clinical Chemistry
PDJ Class II 21 CFR 862.1373
System (75)
H. Intended Use:
1. Intended use(s):
See indication for use below.
1

[Table 1 on page 1]
Product				
	Regulation Name	Classification	Regulation Section	Panel
Code				
				
PDJ	Hemoglobin A1c Test
System	Class II	21 CFR 862.1373	Clinical Chemistry
(75)

--- Page 2 ---
2. Indication(s) for use:
The D-10 Hemoglobin A1c Program is intended for the quantitative determination of
hemoglobin A1c (IFCC mmol/mol and NGSP %) in human whole blood using ion-
exchange high-performance liquid chromatography (HPLC) on the D-10 Hemoglobin
Testing System.
Hemoglobin A1c measurements are used as an aid in diagnosis of diabetes, as an aid to
identify patients who may be at risk for developing diabetes mellitus, and for the
monitoring of long-term blood glucose control in individuals with diabetes mellitus.
The D-10 Hemoglobin A1c Program is intended for professional in vitro diagnostic use
only.
3. Special conditions for use statement(s):
For prescription use only.
The HbA1c test is not intended for analysis of samples collected from newborns.
The HbA1c test should not be used to replace glucose testing in pediatric patients,
pregnant women, or patients with Type 1 diabetes.
In cases of rapidly evolving Type 1 diabetes, the increase of HbA1c values might be
delayed compared to the acute increase in glucose concentrations. In these conditions,
diabetes mellitus must be diagnosed based on plasma glucose concentration and/or the
typical clinical symptoms.
The HbA1c test should not be used to diagnose diabetes during pregnancy or to diagnose
gestational diabetes. HbA1c reflects the average blood glucose levels over the preceding
3 months (the average life of a red blood cell), and therefore may be falsely low during
pregnancy or any other condition associated with recent onset of hyperglycemia and/or
decreased red cell survival.
The HbA1c test should not be used to diagnose diabetes in patients with the following
conditions:
Any condition that alters the life span of the red blood cells, including recent blood
loss, transfusion, significant iron deficiency, hemolytic anemia (including hereditary
spherocytosis) or other hemolytic diseases, hemoglobinopathies and thalassemias, as
the altered red blood cell turnover interferes with the relationship between mean
blood glucose and HbA1c values.
Malignancies or severe chronic hepatic and renal disease.
2

--- Page 3 ---
4. Special instrument requirements:
Bio-Rad D-10 Hemoglobin Testing System
I. Device Description:
The D-10 HbA1c assay is run on the D-10 Hemoglobin Testing System instrument.
The Bio-Rad D-10 HbA1c assay includes the following components:
D-10 HbA1c Analytical Cartridge. Cation exchange cartridge (400 tests), 4.0 mm
x 30 mm.
D-10 Wash/Diluent Solution. Each bottle contains 1600 mL of deionized water
with <0.05% sodium azide as a preservative.
D-10 Elution Buffer 1. Each bottle contains 2000 mL of a Bis-Tris/Phosphate
buffer. Contains <0.05% sodium azide as a preservative.
D-10 Elution Buffer 2. Each bottle contains 1000 mL of a Bis-Tris/Phosphate
buffer. Contains <0.05% sodium azide as a preservative.
D-10 Calibrator/Diluent Set. One set consisting of 3 vials of Calibrator Level 1, 3
vials of Calibrator Level 2, and 1 bottle of Calibrator Diluent. The calibrator vials
contain lyophilized human red blood cell hemolysate with gentamicin,
tobramycin, and EDTA as preservatives. Reconstituted volume is 7 mL per vial.
Calibrator Diluent contains 100 mL of deionized water with <0.05% sodium
azide as a preservative. The D-10 Calibrator/Diluent Set was previously cleared
in k031043.
Whole Blood Primer. Each vial contains lyophilized human red blood cell
hemolysate with gentamicin, tobramycin, and EDTA as preservatives.
Rec onstituted volume is 1.0 mL per vial.
Sample Vials. 100 polypropylene microvials with pierceable caps, 1.5 mL.
J. Substantial Equivalence Information:
1. Predicate device name(s):
VARIANT II TURBO HbA1c Kit -2.0
2. Predicate 510(k) number(s):
k142448
3

[Table 1 on page 3]
D-10 HbA1c Analytical Cartridge. Cation exchange cartridge (400 tests), 4.0 mm
x 30 mm.
D-10 Wash/Diluent Solution. Each bottle contains 1600 mL of deionized water
with <0.05% sodium azide as a preservative.
D-10 Elution Buffer 1. Each bottle contains 2000 mL of a Bis-Tris/Phosphate
buffer. Contains <0.05% sodium azide as a preservative.
D-10 Elution Buffer 2. Each bottle contains 1000 mL of a Bis-Tris/Phosphate
buffer. Contains <0.05% sodium azide as a preservative.
D-10 Calibrator/Diluent Set. One set consisting of 3 vials of Calibrator Level 1, 3
vials of Calibrator Level 2, and 1 bottle of Calibrator Diluent. The calibrator vials
contain lyophilized human red blood cell hemolysate with gentamicin,
tobramycin, and EDTA as preservatives. Reconstituted volume is 7 mL per vial.
Calibrator Diluent contains 100 mL of deionized water with <0.05% sodium
azide as a preservative. The D-10 Calibrator/Diluent Set was previously cleared
in k031043.
Whole Blood Primer. Each vial contains lyophilized human red blood cell
hemolysate with gentamicin, tobramycin, and EDTA as preservatives.
Rec onstituted volume is 1.0 mL per vial.
Sample Vials. 100 polypropylene microvials with pierceable caps, 1.5 mL.

--- Page 4 ---
3. Comparison with predicate:
Similarities
Item D-10 Hemoglobin A1c VARIANT II TURBO
Program HbA1c Kit – 2.0
Candidate Device Predicate Device (k142448)
Intended Use Intended for the quantitative Intended for the quantitative
determination of hemoglobin determination of hemoglobin
A1c (IFCC mmol/mol and A1c (IFCC mmol/mol and NGSP
NGSP %) as an aid in %) as an aid in diagnosis of
diagnosis of diabetes and as diabetes and as an aid in
an aid in identifying patients identifying patients who may be
who may be at risk for at risk for developing diabetes.
developing diabetes, and for
the monitoring of long-term
blood glucose control in
individuals with diabetes
mellitus.
Specimen Type Human Whole blood Same
Assay Principle Ion exchange HPLC Same
Standardization Traceable to the Diabetes Same
Control and Complications
Trial (DCCT) reference
method and IFCC. Certified
via the National
Glycohemoglobin
Standardization Program
(NGSP)
Differences
Item D-10 Hemoglobin A1c VARIANT II TURBO
Program HbA1c Kit – 2.0
Candidate Device Predicate Device (k142448)
Platform D-10 Hemoglobin Testing VARIANTII TURBO
System Hemoglobin Testing System and
VARIANTII TURBO Link
Hemoglobin Testing System
Measuring 3.9 to 18.8% (NSGP) 3.4 to 20.6 % (NSGP)
Range 19 – 182 mmol/mol 14 – 203 mmol/mol
HbA1c (IFCC) HbA1c (IFCC)
4

[Table 1 on page 4]
Similarities		
Item	D-10 Hemoglobin A1c	VARIANT II TURBO
	Program	HbA1c Kit – 2.0
	Candidate Device	Predicate Device (k142448)
		
Intended Use	Intended for the quantitative
determination of hemoglobin
A1c (IFCC mmol/mol and
NGSP %) as an aid in
diagnosis of diabetes and as
an aid in identifying patients
who may be at risk for
developing diabetes, and for
the monitoring of long-term
blood glucose control in
individuals with diabetes
mellitus.	Intended for the quantitative
determination of hemoglobin
A1c (IFCC mmol/mol and NGSP
%) as an aid in diagnosis of
diabetes and as an aid in
identifying patients who may be
at risk for developing diabetes.
Specimen Type	Human Whole blood	Same
Assay Principle	Ion exchange HPLC	Same
Standardization	Traceable to the Diabetes
Control and Complications
Trial (DCCT) reference
method and IFCC. Certified
via the National
Glycohemoglobin
Standardization Program
(NGSP)	Same

[Table 2 on page 4]
Differences		
Item	D-10 Hemoglobin A1c	VARIANT II TURBO
	Program	HbA1c Kit – 2.0
	Candidate Device	Predicate Device (k142448)
		
Platform	D-10 Hemoglobin Testing
System	VARIANTII TURBO
Hemoglobin Testing System and
VARIANTII TURBO Link
Hemoglobin Testing System
Measuring
Range	3.9 to 18.8% (NSGP)
19 – 182 mmol/mol
HbA1c (IFCC)	3.4 to 20.6 % (NSGP)
14 – 203 mmol/mol
HbA1c (IFCC)

--- Page 5 ---
Matrices K2-EDTA, K3-EDTA K2-EDTA, K3-EDTA
Hemoglobin Capillary Collection
Kit
K. Standard/Guidance Document Referenced (if applicable):
CLSI EP05-A2- Evaluation of Precision Performance of Clinical Devices; Approved
Guideline
CLSI EP06-A- Evaluation of the Linearity of Quantitative Measurement Procedure: A
statistical Approach; Approved Guideline
CLSI EP7-A2 Interference Testing in Clinical Chemistry; Approved Guideline-Second
Edition
CLSI EP9-A2-IR – Method Comparison and Bias Estimation Using Patient Samples;
Approved Guideline
CLSI EP12-A2- User Protocol for Evaluation of Qualitative Test Performance; Approved
Guideline
CLSI EP17-A2-Evaluation of Detection Capability for Clinical Laboratory Measurement
Procedures; Approved Guideline
CLSI EP25A-Evaluation of Stability of In Vitro Diagnostic Reagents; Approved Guideline
CLSI EP28-A3-Defining, Establishing and Verifying Reference Intervals in the Clinical
Laboratory; Approved Guideline
L. Test Principle:
The D-10 Hemoglobin A1c Program utilizes principles of ion-exchange high-performance
liquid chromatography (HPLC). The samples are automatically diluted on the D-10 and
injected into the analytical cartridge. The D-10 delivers a programmed buffer gradient of
increasing ionic strength to the cartridge, where the hemoglobins are separated based on their
ionic interactions with the cartridge material. The separated hemoglobins then pass through
the flow cell, where changes in the absorbance at 415 nm are measured.
The D-10 software collects raw data from each analysis and calculates HbA1c values based
on a bi-level calibration curve. A sample report and a chromatogram are generated for each
sample. The A1c peak is shaded. This area is calculated using an exponentially modified
Gaussian (EMG) algorithm.
5

[Table 1 on page 5]
Matrices	K2-EDTA, K3-EDTA	K2-EDTA, K3-EDTA
Hemoglobin Capillary Collection
Kit

--- Page 6 ---
M. Performance Characteristics (if/when applicable):
1. Analytical performance:
a. Precision/Reproducibility:
The precision of the D-10™ Hemoglobin A1c Program was evaluated based on CLSI
EP05-A2 guidelines, Evaluation of Precision Performance of Quantitative Measurement
Methods using a modified study design. Four K3 EDTA whole blood samples at the
following targeted HbA1c concentrations of ~5%, ~6.5%, ~8% and ~12% were utilized
in the study. In addition, five quality control materials were also tested. The samples were
run in duplicate in 2 runs per day on 3 instruments for 20 days. The study was repeated
using 3 different kit lots, yielding a total of 720 results per sample over a 60-day period.
NGSP results are shown in Tables 1-4. IFCC results are shown in Tables 5-8.
Table 1: Instrument 1 (% CV by Sample (NGSP))
Between- Between- Total
HbA1c
Sample Repeatability Run Day Between-Lot Precision
%
ID SD %CV SD %C SD %CV SD %CV SD %CV
Patient 1 5.2 0.07 1.3 0.00 V0 .0 0.04 0.7 0.08 1.6 0.11 2.2
Patient 2 6.7 0.07 1.0 0.00 0.0 0.07 1.1 0.05 0.7 0.11 1.7
Patient 3 8.4 0.05 0.6 0.01 0.2 0.08 1.0 0.02 0.2 0.10 1.2
Patient 4 12.7 0.09 0.7 0.06 0.5 0.17 1.3 0.21 1.7 0.29 2.3
Control 1 5.6 0.07 1.2 0.00 0.0 0.05 0.9 0.05 0.9 0.10 1.8
Control 2 10.4 0.10 0.9 0.00 0.0 0.12 1.1 0.12 1.2 0.20 1.9
QC 1 5.5 0.06 1.0 0.00 0.0 0.05 0.9 0.08 1.5 0.11 2.1
QC 2 10.0 0.13 1.3 0.00 0.0 0.09 0.9 0.06 0.6 0.17 1.7
QC 3 15.6 0.11 0.7 0.15 1.0 0.08 0.5 0.17 1.1 0.27 1.7
Table 2: Instrument 2 (% CV by Sample (NGSP))
Between- Between- Total
HbA1c
Sample ID Repeatability Run Day Between-Lot Precision
%
SD %CV SD %C SD %CV SD %CV SD %CV
Patient 1 5.2 0.04 0.9 0.02 V0 .4 0.04 0.8 0.08 1.5 0.10 1.9
Patient 2 6.6 0.03 0.5 0.04 0.6 0.05 0.8 0.02 0.3 0.08 1.2
Patient 3 8.2 0.04 0.5 0.04 0.4 0.07 0.8 0.02 0.2 0.09 1.0
Patient 4 12.5 0.06 0.5 0.08 0.6 0.13 1.1 0.21 1.7 0.27 2.1
Control 1 5.6 0.04 0.8 0.02 0.3 0.06 1.0 0.07 1.2 0.10 1.7
Control 2 10.1 0.04 0.4 0.06 0.6 0.08 0.8 0.09 0.9 0.14 1.4
QC 1 5.5 0.03 0.6 0.02 0.4 0.06 1.0 0.08 1.5 0.11 1.9
QC 2 9.8 0.07 0.7 0.06 0.6 0.09 0.9 0.04 0.4 0.13 1.4
QC 3 15.2 0.07 0.4 0.08 0.5 0.14 0.9 0.24 1.6 0.29 1.9
6

[Table 1 on page 6]
				Between-		Between-				Total	
	HbA1c										
Sample		Repeatability		Run		Day		Between-Lot		Precision	
	%										
ID		SD	%CV	SD	%C	SD	%CV	SD	%CV	SD	%CV
											
Patient 1	5.2	0.07	1.3	0.00	V0 .0	0.04	0.7	0.08	1.6	0.11	2.2
Patient 2	6.7	0.07	1.0	0.00	0.0	0.07	1.1	0.05	0.7	0.11	1.7
Patient 3	8.4	0.05	0.6	0.01	0.2	0.08	1.0	0.02	0.2	0.10	1.2
Patient 4	12.7	0.09	0.7	0.06	0.5	0.17	1.3	0.21	1.7	0.29	2.3
Control 1	5.6	0.07	1.2	0.00	0.0	0.05	0.9	0.05	0.9	0.10	1.8
Control 2	10.4	0.10	0.9	0.00	0.0	0.12	1.1	0.12	1.2	0.20	1.9
QC 1	5.5	0.06	1.0	0.00	0.0	0.05	0.9	0.08	1.5	0.11	2.1
QC 2	10.0	0.13	1.3	0.00	0.0	0.09	0.9	0.06	0.6	0.17	1.7
QC 3	15.6	0.11	0.7	0.15	1.0	0.08	0.5	0.17	1.1	0.27	1.7

[Table 2 on page 6]
				Between-		Between-				Total	
	HbA1c										
Sample ID		Repeatability		Run		Day		Between-Lot		Precision	
	%										
		SD	%CV	SD	%C	SD	%CV	SD	%CV	SD	%CV
											
Patient 1	5.2	0.04	0.9	0.02	V0 .4	0.04	0.8	0.08	1.5	0.10	1.9
Patient 2	6.6	0.03	0.5	0.04	0.6	0.05	0.8	0.02	0.3	0.08	1.2
Patient 3	8.2	0.04	0.5	0.04	0.4	0.07	0.8	0.02	0.2	0.09	1.0
Patient 4	12.5	0.06	0.5	0.08	0.6	0.13	1.1	0.21	1.7	0.27	2.1
Control 1	5.6	0.04	0.8	0.02	0.3	0.06	1.0	0.07	1.2	0.10	1.7
Control 2	10.1	0.04	0.4	0.06	0.6	0.08	0.8	0.09	0.9	0.14	1.4
QC 1	5.5	0.03	0.6	0.02	0.4	0.06	1.0	0.08	1.5	0.11	1.9
QC 2	9.8	0.07	0.7	0.06	0.6	0.09	0.9	0.04	0.4	0.13	1.4
QC 3	15.2	0.07	0.4	0.08	0.5	0.14	0.9	0.24	1.6	0.29	1.9

--- Page 7 ---
Table 3: Instrument 3 (% CV by Sample (NGSP))
Between- Between- Total
Sample HbA1c Repeatability Run Day Between-Lot Precision
ID % SD %CV SD %CV SD %CV SD %CV SD %CV
Patient 1 5.2 0.06 1.2 0.00 0.0 0.06 1.2 0.05 0.9 0.10 1.9
Patient 2 6.7 0.05 0.7 0.02 0.3 0.08 1.2 0.00 0.0 0.09 1.4
Patient 3 8.3 0.05 0.6 0.03 0.4 0.11 1.3 0.04 0.5 0.13 1.6
Patient 4 12.7 0.07 0.6 0.07 0.6 0.17 1.3 0.21 1.6 0.29 2.2
Control 1 5.6 0.05 0.9 0.00 0.0 0.07 1.2 0.04 0.8 0.10 1.7
Control 2 10.3 0.08 0.8 0.05 0.5 0.14 1.3 0.08 0.8 0.19 1.8
QC 1 5.5 0.04 0.8 0.02 0.3 0.07 1.2 0.07 1.3 0.11 2.0
QC 2 9.9 0.09 0.9 0.00 0.0 0.12 1.2 0.13 1.3 0.20 2.0
QC 3 15.5 0.10 0.6 0.11 0.7 0.18 1.1 0.07 0.4 0.24 1.6
Table 4: Instruments Combined (% CV by Sample (NGSP))
Between Between Between Between Total
Sample HbA1c Repeatability Run Day Instruments Lot Precision
ID % SD % SD % SD % SD % SD % SD %
CV CV CV CV CV CV
Patient 5.2 0.06 1.2 0.00 0.0 0.05 0.9 0.00 0.0 0.07 1.4 0.10 2.0
1
Patient 6.7 0.05 0.8 0.01 0.2 0.07 1.0 0.05 0.8 0.03 0.5 0.11 1.6
2
Patient 8.3 0.05 0.6 0.03 0.3 0.09 1.1 0.08 0.9 0.03 0.3 0.13 1.6
3
Patient 12.7 0.08 0.6 0.07 0.6 0.16 1.2 0.00 0.0 0.21 1.7 0.28 2.2
4
Control 5.6 0.06 1.0 0.00 0.0 0.06 1.0 0.00 0.0 0.05 0.9 0.10 1.7
1
Control 10.3 0.08 0.7 0.04 0.4 0.12 1.1 0.14 1.3 0.10 1.0 0.22 2.2
2
QC 1 5.5 0.05 0.8 0.00 0.1 0.06 1.0 0.00 0.0 0.08 1.4 0.11 2.0
QC 2 9.9 0.10 1.0 0.00 0.0 0.10 1.0 0.05 0.5 0.09 0.9 0.17 1.8
QC 3 15.4 0.09 0.6 0.12 0.8 0.14 0.9 0.20 1.3 0.17 1.1 0.34 2.2
7

[Table 1 on page 7]
				Between-		Between-				Total	
Sample	HbA1c	Repeatability		Run		Day		Between-Lot		Precision	
ID	%	SD	%CV	SD	%CV	SD	%CV	SD	%CV	SD	%CV
Patient 1	5.2	0.06	1.2	0.00	0.0	0.06	1.2	0.05	0.9	0.10	1.9
Patient 2	6.7	0.05	0.7	0.02	0.3	0.08	1.2	0.00	0.0	0.09	1.4
Patient 3	8.3	0.05	0.6	0.03	0.4	0.11	1.3	0.04	0.5	0.13	1.6
Patient 4	12.7	0.07	0.6	0.07	0.6	0.17	1.3	0.21	1.6	0.29	2.2
Control 1	5.6	0.05	0.9	0.00	0.0	0.07	1.2	0.04	0.8	0.10	1.7
Control 2	10.3	0.08	0.8	0.05	0.5	0.14	1.3	0.08	0.8	0.19	1.8
QC 1	5.5	0.04	0.8	0.02	0.3	0.07	1.2	0.07	1.3	0.11	2.0
QC 2	9.9	0.09	0.9	0.00	0.0	0.12	1.2	0.13	1.3	0.20	2.0
QC 3	15.5	0.10	0.6	0.11	0.7	0.18	1.1	0.07	0.4	0.24	1.6

[Table 2 on page 7]
				Between		Between		Between		Between		Total	
Sample	HbA1c	Repeatability		Run		Day		Instruments		Lot		Precision	
ID	%	SD	%	SD	%	SD	%	SD	%	SD	%	SD	%
			CV		CV		CV		CV		CV		CV
Patient
1	5.2	0.06	1.2	0.00	0.0	0.05	0.9	0.00	0.0	0.07	1.4	0.10	2.0
Patient
2	6.7	0.05	0.8	0.01	0.2	0.07	1.0	0.05	0.8	0.03	0.5	0.11	1.6
Patient
3	8.3	0.05	0.6	0.03	0.3	0.09	1.1	0.08	0.9	0.03	0.3	0.13	1.6
Patient
4	12.7	0.08	0.6	0.07	0.6	0.16	1.2	0.00	0.0	0.21	1.7	0.28	2.2
Control
1	5.6	0.06	1.0	0.00	0.0	0.06	1.0	0.00	0.0	0.05	0.9	0.10	1.7
Control
2	10.3	0.08	0.7	0.04	0.4	0.12	1.1	0.14	1.3	0.10	1.0	0.22	2.2
QC 1	5.5	0.05	0.8	0.00	0.1	0.06	1.0	0.00	0.0	0.08	1.4	0.11	2.0
QC 2	9.9	0.10	1.0	0.00	0.0	0.10	1.0	0.05	0.5	0.09	0.9	0.17	1.8
QC 3	15.4	0.09	0.6	0.12	0.8	0.14	0.9	0.20	1.3	0.17	1.1	0.34	2.2

--- Page 8 ---
Table 5: Instrument 1 (% CV by Sample (IFCC Units- mmol/mol))
HbA1c Repeatability Between-Run Between-Day Between-Lot Total Precision
Sample mmol/ SD %CV SD %CV SD %CV SD %CV SD %
ID mol C
V
Patient 1 33 0.76 2.3 0.00 0.0 0.40 1.2 0.89 2.7 1.24 3
Patient 2 50 0.76 1.5 0.00 0.0 0.81 1.6 0.54 1.1 1.23 .2
Patient 3 68 0.53 0.8 0.16 0.2 0.92 1.3 0.17 0.3 1.08
7.1
Patient 4 116 1.01 0.9 0.65 0.6 1.85 1.6 2.31 2.0 3.19
5.2
Control 1 38 0.77 2.0 0.00 0.0 0.56 1.5 0.53 1.4 1.09
6.2
Control 2 91 1.08 1.2 0.00 0.0 1.31 1.4 1.34 1.5 2.16
8.2
QC 1 37 0.63 1.7 0.00 0.0 0.53 1.4 0.93 2.5 1.25 9.3
QC 2 86 1.46 1.7 0.00 0.0 0.96 1.1 0.61 0.7 1.85 4.2
QC 3 147 1.25 0.9 1.67 1.1 0.92 0.6 1.90 1.3 2.96
4.2
2.
0
Table 6: Instrument 2 (% CV by Sample (IFCC Units- mmol/mol))
HbA1c Repeatability Between-Run Between-Day Between-Lot Total Precision
Sample mmol/ SD %CV SD %CV SD %CV SD %CV SD %CV
ID mol
Patient 1 33 0.49 1.5 0.20 0.6 0.43 1.3 0.84 2.6 1.08 3.3
Patient 2 49 0.36 0.7 0.42 0.9 0.58 1.2 0.24 0.5 0.83 1.7
Patient 3 66 0.40 0.6 0.38 0.6 0.72 1.1 0.19 0.3 0.93 1.4
Patient 4 113 0.63 0.6 0.88 0.8 1.47 1.3 2.27 2.0 2.91 2.6
Control 1 37 0.46 1.2 0.19 0.5 0.61 1.6 0.70 1.9 1.05 2.8
Control 2 87 0.45 0.5 0.66 0.8 0.89 1.0 0.96 1.1 1.54 1.8
QC 1 37 0.38 1.0 0.21 0.6 0.61 1.7 0.91 2.5 1.18 3.2
QC 2 84 0.72 0.9 0.67 0.8 1.00 1.2 0.43 0.5 1.46 1.7
QC 3 142 0.73 0.5 0.83 0.6 1.52 1.1 2.58 1.8 3.19 2.2
Table 7: Instrument 3 (% CV by Sample (IFCC Units- mmol/mol))
HbA1c Repeatability Between-Run Between-Day Between-Lot Total Precision
Sample
mmol/
ID SD %CV SD %CV SD %CV SD %CV SD %CV
mol
Patient 1 33 0.70 2.1 0.00 0.0 0.66 2.0 0.51 1.6 1.09 3.3
Patient 2 50 0.51 1.0 0.22 0.4 0.85 1.7 0.00 0.0 1.02 2.0
Patient 3 68 0.56 0.8 0.33 0.5 1.20 1.8 0.46 0.7 1.44 2.1
Patient 4 115 0.80 0.7 0.80 0.7 1.81 1.6 2.26 2.0 3.11 2.7
Control 37 0.57 1.5 0.00 0.0 0.73 2.0 0.46 1.2 1.03 2.8
1C ontrol 89 0.87 1.0 0.60 0.7 1.51 1.7 0.93 1.0 2.07 2.3
2Q C 1 36 0.45 1.2 0.18 0.5 0.73 2.0 0.77 2.1 1.16 3.2
QC 2 85 1.00 1.2 0.00 0.0 1.35 1.6 1.44 1.7 2.21 2.6
QC 3 145 1.05 0.7 1.24 0.9 1.93 1.3 0.74 0.5 2.63 1.8
8

[Table 1 on page 8]
	HbA1c	Repeatability		Between-Run		Between-Day		Between-Lot		Total Precision
Sample	mmol/	SD	%CV	SD	%CV	SD	%CV	SD	%CV	SD
ID	mol									
										
Patient 1	33	0.76	2.3	0.00	0.0	0.40	1.2	0.89	2.7	1.24
Patient 2	50	0.76	1.5	0.00	0.0	0.81	1.6	0.54	1.1	1.23
Patient 3	68	0.53	0.8	0.16	0.2	0.92	1.3	0.17	0.3	1.08
Patient 4	116	1.01	0.9	0.65	0.6	1.85	1.6	2.31	2.0	3.19
Control 1	38	0.77	2.0	0.00	0.0	0.56	1.5	0.53	1.4	1.09
Control 2	91	1.08	1.2	0.00	0.0	1.31	1.4	1.34	1.5	2.16
QC 1	37	0.63	1.7	0.00	0.0	0.53	1.4	0.93	2.5	1.25
QC 2	86	1.46	1.7	0.00	0.0	0.96	1.1	0.61	0.7	1.85
QC 3	147	1.25	0.9	1.67	1.1	0.92	0.6	1.90	1.3	2.96

[Table 2 on page 8]
	HbA1c	Repeatability		Between-Run		Between-Day		Between-Lot		Total Precision	
Sample	mmol/	SD	%CV	SD	%CV	SD	%CV	SD	%CV	SD	%CV
ID	mol										
Patient 1	33	0.49	1.5	0.20	0.6	0.43	1.3	0.84	2.6	1.08	3.3
Patient 2	49	0.36	0.7	0.42	0.9	0.58	1.2	0.24	0.5	0.83	1.7
Patient 3	66	0.40	0.6	0.38	0.6	0.72	1.1	0.19	0.3	0.93	1.4
Patient 4	113	0.63	0.6	0.88	0.8	1.47	1.3	2.27	2.0	2.91	2.6
Control 1	37	0.46	1.2	0.19	0.5	0.61	1.6	0.70	1.9	1.05	2.8
Control 2	87	0.45	0.5	0.66	0.8	0.89	1.0	0.96	1.1	1.54	1.8
QC 1	37	0.38	1.0	0.21	0.6	0.61	1.7	0.91	2.5	1.18	3.2
QC 2	84	0.72	0.9	0.67	0.8	1.00	1.2	0.43	0.5	1.46	1.7
QC 3	142	0.73	0.5	0.83	0.6	1.52	1.1	2.58	1.8	3.19	2.2

[Table 3 on page 8]
	HbA1c	Repeatability		Between-Run		Between-Day		Between-Lot		Total Precision	
Sample											
	mmol/										
ID		SD	%CV	SD	%CV	SD	%CV	SD	%CV	SD	%CV
	mol										
											
											
Patient 1	33	0.70	2.1	0.00	0.0	0.66	2.0	0.51	1.6	1.09	3.3
Patient 2	50	0.51	1.0	0.22	0.4	0.85	1.7	0.00	0.0	1.02	2.0
Patient 3	68	0.56	0.8	0.33	0.5	1.20	1.8	0.46	0.7	1.44	2.1
Patient 4	115	0.80	0.7	0.80	0.7	1.81	1.6	2.26	2.0	3.11	2.7
Control	37	0.57	1.5	0.00	0.0	0.73	2.0	0.46	1.2	1.03	2.8
1C ontrol	89	0.87	1.0	0.60	0.7	1.51	1.7	0.93	1.0	2.07	2.3
2Q C 1	36	0.45	1.2	0.18	0.5	0.73	2.0	0.77	2.1	1.16	3.2
QC 2	85	1.00	1.2	0.00	0.0	1.35	1.6	1.44	1.7	2.21	2.6
QC 3	145	1.05	0.7	1.24	0.9	1.93	1.3	0.74	0.5	2.63	1.8

--- Page 9 ---
Table 8: Instruments Combined (% CV by Sample (IFCC Units- mmol/mol))
Between Between Between Between Total
Sample HbA1 Repeatability Run Day Instruments Lot Precision
ID mmol/ SD % SD % SD % SD % SD % SD %
mol CV CV CV CV CV CV
Patient 33 0.66 2.0 0.00 0.0 0.51 1.5 0.00 0.0 0.77 2.3 1.13 3.4
1
Patient 50 0.57 1.1 0.13 0.3 0.76 1.5 0.58 1.2 0.34 0.7 1.17 2.3
2
Patient 67 0.50 0.7 0.31 0.5 0.96 1.4 0.84 1.3 0.30 0.4 1.44 2.1
3
Patient 115 0.83 0.7 0.78 0.7 1.72 1.5 0.00 0.0 2.29 2.0 3.08 2.7
4
Control 37 0.60 1.6 0.00 0.0 0.63 1.7 0.00 0.0 0.57 1.5 1.04 2.8
1
Control 89 0.84 0.9 0.48 0.5 1.26 1.4 1.49 1.7 1.09 1.2 2.44 2.7
2
QC 1 37 0.50 1.4 0.04 0.1 0.63 1.7 0.00 0.0 0.88 2.4 1.20 3.2
QC 2 85 1.10 1.3 0.00 0.0 1.12 1.3 0.59 0.7 0.93 1.1 1.92 2.3
QC 3 145 1.04 0.7 1.29 0.9 1.52 1.0 2.22 1.5 1.90 1.3 3.69 2.5
b. Linearity/assay reportable range:
A linearity study was performed per CLSI EP06-A: Evaluation of the Linearity of
Quantitative Measuring Procedures; A Statistical Approach. Linearity across the
reportable range was performed using low 3.9% HbA1c (19 mmol/mol) and high
18.8% HbA1c (182 mmol/mol) K3 EDTA whole blood patient samples. These
samples were mixed together in varying ratios to obtain 9 intermediate sample levels.
The measured values were compared to the expected values. The regression
parameters (slope, intercept, and r2) follow:
NGSP:
Slope Intercept r2 Concentration Range Tested
1.0091 -0.1465 0.9995 3.9 – 18.8 % HbA1c
IFCC:
Slope Intercept r2 Concentration Range Tested
1.0091 -1.3867 0.9995 19 – 182 mmol/mol HbA1c
The linearity study supports the device’s claimed assay measuring range of 3.9 to 18.8%
HbA1c (NGSP) and 19 to 182 mmol/mol HbA1c (IFCC).
9

[Table 1 on page 9]
				Between		Between		Between		Between		Total	
Sample	HbA1	Repeatability		Run		Day		Instruments		Lot		Precision	
ID	mmol/	SD	%	SD	%	SD	%	SD	%	SD	%	SD	%
	mol		CV		CV		CV		CV		CV		CV
Patient
1	33	0.66	2.0	0.00	0.0	0.51	1.5	0.00	0.0	0.77	2.3	1.13	3.4
Patient
2	50	0.57	1.1	0.13	0.3	0.76	1.5	0.58	1.2	0.34	0.7	1.17	2.3
Patient
3	67	0.50	0.7	0.31	0.5	0.96	1.4	0.84	1.3	0.30	0.4	1.44	2.1
Patient
4	115	0.83	0.7	0.78	0.7	1.72	1.5	0.00	0.0	2.29	2.0	3.08	2.7
Control
1	37	0.60	1.6	0.00	0.0	0.63	1.7	0.00	0.0	0.57	1.5	1.04	2.8
Control
2	89	0.84	0.9	0.48	0.5	1.26	1.4	1.49	1.7	1.09	1.2	2.44	2.7
QC 1	37	0.50	1.4	0.04	0.1	0.63	1.7	0.00	0.0	0.88	2.4	1.20	3.2
QC 2	85	1.10	1.3	0.00	0.0	1.12	1.3	0.59	0.7	0.93	1.1	1.92	2.3
QC 3	145	1.04	0.7	1.29	0.9	1.52	1.0	2.22	1.5	1.90	1.3	3.69	2.5

[Table 2 on page 9]
Slope	Intercept			r2		Concentration Range Tested	
1.0091	-0.1465		0.9995		3.9 – 18.8 % HbA1c		

[Table 3 on page 9]
Slope	Intercept			r2		Concentration Range Tested	
1.0091	-1.3867		0.9995		19 – 182 mmol/mol HbA1c		

--- Page 10 ---
c. Traceability, Stability, Expected values (controls, calibrators, or methods):
Traceability:
The D-10 Hemoglobin A1c test standardization is traceable to the International
Federation of Clinical Chemistry (IFCC) reference calibrators.
The D-10 Hemoglobin A1c assay is NGSP certified. The NGSP certification expires
in one year. See NGDP website for current certification at http://www.ngsp.org.
The derived results of (%) from the NGSP correlation are calculated from the
individual quantitative results for Hemoglobin A1c (HbA1c). The International
Federation of Clinical Chemistry (IFCC) units of mmol/mol are calculated using the
Master Equation NGSP (%) = 0.09148 x IFCC (mmol/mol) + 2.152. HbA1c results
are available to the customer using two different units: NGSP equivalent units (%)
and IFCC equivalent units (mmol/mol).
Controls and calibrators:
D-10 Hemoglobin A1c Calibrators are recommended for use with this device. Value
assignment and stability protocols and acceptance criteria were previously reviewed
and cleared in k031043.
Bio-Rad recommends commercially available control materials; Lyphochek Diabetes
Control was previously cleared in k070546 and Liquichek Diabetes Control was
previously cleared in submission k052838.
Sample Stability:
A sample stability study was conducted to show the stability of frozen samples
collected in K2 and K3EDTA. Samples with concentration values spanning 3.9% to
17.0% HbA1c were collected in K2-EDTA tubes, samples with concentration values
spanning 3.9% to 17.1% HbA1c were collected in K3-EDTA tubes. The aliquots of
the whole blood samples were placed at -70°C for twelve months. Study protocols
were reviewed and found to be acceptable. The data supports the use of K2-EDTA
tubes and K3-EDTA tubes with frozen whole blood aliquoted and stored at -70°C for
up to for 12 months when using the D-10™ Hemoglobin A1c Program.
d. Detection limit:
The claimed measuring range of 3.9 to 18.8% HbA1c for D-10 Hemoglobin A1c
Program is based on linearity, see 1b.
10

--- Page 11 ---
e. Analytical specificity:
Endogenous Interference:
An Endogenous Interference study was performed per CLSI EP07-A2, Interference
Testing in Clinical Chemistry. Two EDTA whole blood sample pools were evaluated
using a low level whole blood sample with a concentration ~6.5% HbA1c and a high
level whole blood sample with a concentration of HbA1c of ~8.0%.
Ten replicates of each pool prepared with the test and control samples were analyzed
using the D-10 Hemoglobin A1c on the D-10 Hemoglobin Testing System.
Significant interference was defined as a greater than ±7% change in %HbA1c value
of the mean of the test samples relative to the mean of the reference samples.
The following endogenous substances showed no significant interference at the
concentrations described below:
Concentration
Endogenous substance (Conventional Units)
Lipemia (Intralipid) 6000 mg/dL
Conjugated bilirubin 60 mg/dL
Unconjugated bilirubin 60 mg/dL
Glucose 2000 mg/dL
Rheumatoid factor 750 IU/mL
Total protein 21 g/dL
Drug Interference:
A Drug Interference study was performed based per CLSI EP07-A2, Interference
Testing in Clinical Chemistry. Two EDTA whole blood sample pools were evaluated
using a low level whole blood sample with a concentration ~6.5%HbA1c and a high
level whole blood sample with a concentration of ~8.0%HbA1c. Test samples were
prepared by spiking each drug at the interferent concentration shown in Table 18. Ten
replicates of each drug prepared with the test and control samples were analyzed
using the D-10 Hemoglobin A1c on the D-10 Hemoglobin Testing System.
Significant interference was defined as a greater than ±7% change in %HbA1c value
of the mean of the test samples relative to the mean of the reference samples. No
significant interference was observed at therapeutic levels up to the stated
concentrations as shown below:
11

[Table 1 on page 11]
Endogenous substance	Concentration
(Conventional Units)
Lipemia (Intralipid)	6000 mg/dL
Conjugated bilirubin	60 mg/dL
Unconjugated bilirubin	60 mg/dL
Glucose	2000 mg/dL
Rheumatoid factor	750 IU/mL
Total protein	21 g/dL

--- Page 12 ---
Potential Drug Concentration
Interferent
Acetylcysteine 166 mg/dL
Ampicillin-Na 1000 mg/dL
Ascorbic acid 300 mg/dL
Cefoxitin 2500 mg/dL
Heparin 5000 U/L
Levodopa 20 mg/dL
Methyldopa 20 mg/dL
Metronidazole 200 mg/dL
Doxycyclin 50 mg/dL
Acetylsalicylic acid 1000 mg/dL
Rifampicin 64 mg/L
Cyclosporine 5 mg/L
Acetaminophen 200 mg/L
Ibuprofen 500 mg/L
Theophylline 100 mg/L
Phenylbutazone 400 mg/L
Cross Reactivity with Hemoglobin Derivatives:
A Hemoglobin Derivatives Interference study was performed based on CLSI
EP07-A2, Interference Testing in Clinical Chemistry. Potential interference from
Acetylated hemoglobin (Hb), Carbamylated hemoglobin (Hb) and Labile HbA1c
were evaluated using a low level whole blood EDTA sample with a concentration
~6.5%HbA1c and a high level whole blood EDTA sample with a concentration of
~8.0% HbA1c. The potentially interfering hemoglobin derivatives were spiked
12

[Table 1 on page 12]
Potential Drug
Interferent	Concentration
Acetylcysteine	166 mg/dL
Ampicillin-Na	1000 mg/dL
Ascorbic acid	300 mg/dL
Cefoxitin	2500 mg/dL
Heparin	5000 U/L
Levodopa	20 mg/dL
Methyldopa	20 mg/dL
Metronidazole	200 mg/dL
Doxycyclin	50 mg/dL
Acetylsalicylic acid	1000 mg/dL
Rifampicin	64 mg/L
Cyclosporine	5 mg/L
Acetaminophen	200 mg/L
Ibuprofen	500 mg/L
Theophylline	100 mg/L
Phenylbutazone	400 mg/L

--- Page 13 ---
into the low and high level blood samples and each sample was analyzed using ten
replicates each in the same analytical run on the D-10 Hemoglobin Testing System
with the D-10 Hemoglobin A1c.
Significant interference was defined as more than a ±7% change in HbA1c value
from the control. The test result conclusions are as follows:
• Acetylated Hb up to 49 mg/dL acetylsalicylic acid does not interfere with
this assay.
• Carbamylated Hb up to 10 mg/dL potassium cyanate does not interfere with
this assay.
• Labile A1c up to 1000 mg/dL glucose does not interfere with this assay.
Hemoglobin Variant Study:
A Hemoglobin Variant study was performed using a total of 87 normal and
diabetic whole blood EDTA patent variant samples known to contain hemoglobin
variants S, C, E, D, A2 and F. Testing of the samples containing hemoglobin
variants S, C, E, and D, A2 and F were performed using the D-10 Hemoglobin
A1c on the D-10 Hemoglobin Testing System and compared to results obtained
by a NGSP reference method that has been demonstrated to be free from the
hemoglobin interferent (Trinity Biotech Ultra2 A1c, Trinity Biotech Premier
Hb9210 and Tosoh G8 analyzers). The test result conclusions are as follows:
Variant samples used in Hemoglobin Variant Study
Hemoglobin Range in % Abnormal Range in %HbA1c
Variant n Variant Concentration
HbS 22 31 – 43 5.6 – 11.5
HbC 20 31 – 40 5.0 – 10.7
HbD 22 35 – 43 5.8 – 10.0
HbE 23 21 – 32 5.9 – 11.6
HbA2 20 5.0 – 6.2 5.0 - 14.5
HbF 24 3.3 – 32.6 4.7 - 14.4
13

[Table 1 on page 13]
Hemoglobin
Variant	n	Range in % Abnormal
Variant	Range in %HbA1c
Concentration
HbS	22	31 – 43	5.6 – 11.5
HbC	20	31 – 40	5.0 – 10.7
HbD	22	35 – 43	5.8 – 10.0
HbE	23	21 – 32	5.9 – 11.6
HbA2	20	5.0 – 6.2	5.0 - 14.5
HbF	24	3.3 – 32.6	4.7 - 14.4

--- Page 14 ---
Hemoglobin Variant Study Bias Results
Hemoglobin Relative % Bias to Comparative Method
Variant
Relative %Bias Relative %Bias
(Range of %Bias) (Range of %Bias)
for HbA1c for HbA1c
~6.5% ~9.0%
HbS 1.1 (-4.7 to 4.9) 0.2 (-6.1 to5.3)
HbC 2.6 (1.4 to 5.9) -0.9 (-2.8 to 0.9)
HbD -0.6 (-3.1 to 4.7) 1.7 (-3.6 to 5.1)
HbE 0.5 (-3.3 to 6.2) 2.8 (1.2 to 5.2)
HbA2 0.6 (-1.8 to 1.8) -1.7 (-2.8 to -0.7)
HbF 3.1 (-1.5 to 8.8) -0.6 (-2.5 to 4.8)
Significant interference was defined as ≥ ±7% change in HbA1c value in the presence
of the hemoglobin variant relative to control. The results show there is no significant
interference for HbS (≤43.0%), HbC (≤40.0%), HbD (≤43.0%), HbE (≤32.0%) and
HbA2 (≤6.0%) and HbF (≤ 10%) at the concentrations tested in this study. The
labeling states;
This device has significant positive interference with fetal hemoglobin (HbF).
HbA1c results are invalid for patients with abnormal amounts of HbF,
including those with known Hereditary Persistence of Fetal Hemoglobin.
Hemoglobin F concentrations up to 10% do not interfere with the test. Any
sample with HbF >10% may result in higher than expected HbA 1c values.
Any sample with HbF >5% should be suspected of having a
hemoglobinopathy.
f. Assay cut-off:
Not applicable
2. Comparison studies:
a. Method comparison with predicate device:
A Method comparison study was performed per CLSI EP09-A3, Measurement
Procedure Comparison and Bias Estimation Using Patient Samples. 128 variant-free
whole blood K3 EDTA samples covering the measuring range were evaluated using
the D-10 Hemoglobin A1c Program on the D-10 Hemoglobin Testing System.
Samples were tested in singlicate over four days. The results were compared to
testing performed at a NGSP Secondary Reference Laboratory using a previously
cleared HPLC HbA1c assay method (Tosoh G8 HPLC analyzer). To support the
diagnostic claim, the distribution of samples spanned around the clinical decision
14

[Table 1 on page 14]
Hemoglobin
Variant	Relative % Bias to Comparative Method	
	Relative %Bias
(Range of %Bias)
for HbA1c	Relative %Bias
(Range of %Bias)
for HbA1c
	~6.5%	~9.0%
HbS	1.1 (-4.7 to 4.9)	0.2 (-6.1 to5.3)
HbC	2.6 (1.4 to 5.9)	-0.9 (-2.8 to 0.9)
HbD	-0.6 (-3.1 to 4.7)	1.7 (-3.6 to 5.1)
HbE	0.5 (-3.3 to 6.2)	2.8 (1.2 to 5.2)
HbA2	0.6 (-1.8 to 1.8)	-1.7 (-2.8 to -0.7)
HbF	3.1 (-1.5 to 8.8)	-0.6 (-2.5 to 4.8)

--- Page 15 ---
point as follows in the table below.
Distribution of samples
Hemoglobin A1c level n % of Samples tested
≤ 5% 4 3.1
19 14.8
5 – 6%
33 25.8
6 – 6.5%
33 25.8
6.5 – 7%
20 15.6
7 – 8%
10 7.8
8 – 9%
9 7.0
> 9%
Total samples 128 100.0
Linear, Deming (weighted), and Passing-Bablok regression analyses were performed
for the D-10 Hemoglobin A1c Program on the D-10 Hemoglobin Testing System
versus the comparative G8 HPLC method (NGSP) and are summarized below:
Summary of Method Comparison Results
Slope 95% CI y-Intercept 95% CI R²
Linear
0.9701 0.9587 – 0.9816 0.1801 0.0980 – 0.2622 0.9955
Deming 0.9722 0.9579 – 0.9866 0.1654 0.0637 – 0.2670 1.0000
Passing-Bablok 1.0000 1.0000 – 1.0000 0.0000 0.0000 – 0.0000 1.0000
15

[Table 1 on page 15]
Hemoglobin A1c level	n	% of Samples tested
≤ 5%	4	3.1
5 – 6%	19	14.8
6 – 6.5%	33	25.8
6.5 – 7%	33	25.8
7 – 8%	20	15.6
8 – 9%	10	7.8
> 9%	9	7.0
Total samples	128	100.0

[Table 2 on page 15]
	Slope	95% CI	y-Intercept	95% CI	R²
Linear	0.9701	0.9587 – 0.9816	0.1801	0.0980 – 0.2622	0.9955
Deming	0.9722	0.9579 – 0.9866	0.1654	0.0637 – 0.2670	1.0000
Passing-Bablok	1.0000	1.0000 – 1.0000	0.0000	0.0000 – 0.0000	1.0000

--- Page 16 ---
Scatter Plot using Deming Fit, %HbA1c, NGSP vs. D-10 HbA1c
Scatter Plot using Passing-Bablok Fit, %HbA1c, NGSP vs. D-10 HbA1c
The following biases between D-10 Hemoglobin A1c run on the D-10HbA1c Testing System
versus the NGSP Reference Method (Tosoh G8 HPLC analyzer) were observed:
16

--- Page 17 ---
Bias Estimation
% HbA1c – Decision Level Bias % Bias
5.0±0.5 -0.05 -0.96
6.5±0.5 0.00 0.03
8.0±0.5 -0.08 -0.98
12.0±1.0 -0.10 -0.87
Total Error Calculations:
Using the results of bias estimation (%Bias) in the method comparison study and precision
estimates in the reproducibility study, Total Error (TE) at four concentrations: (5.0 %, 6.5%,
8.0% and 12.0%) were calculated as follows: %TE=|%Bias| + 1.96 *CV* (1 + %Bias). The
results are as follows:
Total Error Estimation
% A1c – Decision Level % Bias % CV % TE
5.0 0.96 2.0 4.9
6.5 0.03 1.6 3.2
8.0 0.98 1.6 4.1
12.0 0.87 2.2 5.2
b. Matrix comparison:
The matrix comparison study was performed, based on CLSI guidance documents
EP14-A2, Vol 25, No 4 "Evaluation of Matrix Effect: Approved Guideline -
Second Edition, EP09-A3, Vol 33, No. 11 "Measurement Procedure Comparison
and Bias Estimation Using Patient samples; Approved Guideline – Third Edition.
Whole blood samples from 44 patients were collected in K3-EDTA sample tubes
and K2-EDTA sample tubes. Once the blood samples were collected, they were
kept at 2-8° C and shipped to Bio Rad Laboratories, CSD, within 1 day of draw.
Analyses were performed once the samples were received. To cover both extreme
ends of the measuring range one high sample was prepared by adding purified
A1c and one low sample by adding purified Ao to non-variant whole blood
samples. The two (2) spiked samples were less than 15% of the total forty four
(44) samples analyzed. Linear regression analysis was performed using K3-EDTA
results as the reference and the results are summarized below:
Sample N Sample Slope Intercept R2
Type Ranges (% A1c) (95% Cl) (95% Cl)
K2- 44 4.1-17.5 1.0077 -0.0383 0.9990
EDTA (0.9980-1.0174) (-0.1154-0.0388)
17

[Table 1 on page 17]
% HbA1c – Decision Level	Bias	% Bias
5.0±0.5	-0.05	-0.96
6.5±0.5	0.00	0.03
8.0±0.5	-0.08	-0.98
12.0±1.0	-0.10	-0.87

[Table 2 on page 17]
% A1c – Decision Level	% Bias	% CV	% TE
5.0	0.96	2.0	4.9
6.5	0.03	1.6	3.2
8.0	0.98	1.6	4.1
12.0	0.87	2.2	5.2

[Table 3 on page 17]
Sample
Type	N	Sample
Ranges (% A1c)	Slope
(95% Cl)	Intercept
(95% Cl)	R2
K2-
EDTA	44	4.1-17.5	1.0077
(0.9980-1.0174)	-0.0383
(-0.1154-0.0388)	0.9990

--- Page 18 ---
The data support the use of K3-EDTA blood collection tubes with fresh whole blood with
the D-10 Hemoglobin A1c System.
3. Clinical studies:
a. Clinical Sensitivity:
Not applicable
b. Clinical specificity:
Not applicable
c. Other clinical supportive data (when a. and b. are not applicable):
Not applicable
4. Clinical cut-off:
Not applicable
5. Expected values/Reference range:
Hemoglobin A1c Expected Values
Hemoglobin A1c
Suggested Diagnosis
NGSP % IFCC mmol/mol
>6.5 >48 Diabetic
5.7 – 6.4 39-47 Pre-Diabetic
<5.7 <39 Non-Diabetic
The expected HbA1c range for non-diabetic adults is 4-6%.
The following references were cited:
• American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus.
Diabetes Care 2014, 37 (Suppl. 1), S81–S90
• World Health Organization. Use of Glycated Haemoglobin (HbA1c) in the
Diagnosis of Diabetes Mellitus.
http://www.who.int/diabetes/publications/diagnosisdiabetes2011/en /
• Clinical Diabetes. Your A1CResults: What Do They Mean?
http://clinical.diabetesjournals.org/content/24/1/9.full.pdf+html
18

[Table 1 on page 18]
Hemoglobin A1c		Suggested Diagnosis
NGSP %	IFCC mmol/mol	
>6.5	>48	Diabetic
5.7 – 6.4	39-47	Pre-Diabetic
<5.7	<39	Non-Diabetic

--- Page 19 ---
N. Proposed Labeling:
The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.
O. Conclusion:
The submitted information in this premarket notification is complete and supports a
substantial equivalence decision.
19